from
Precision Clinical Intelligence Ltd

MAb evolution becomes treatment revolution

What is MABVIEWER?

MABVIEWER is a revolutionary Software-as-a-Medical Device platform that combines existing molecular imaging technology with our patented algorithms to quantify patient response to a monoclonal antibody. Potential applications include:

Monoclonal antibody selection

MABVIEWER guides monoclonal antibody selection to improve patient outcomes.

Informing clinical trial design

MABVIEWER informs clinical trial design through identification of responder populations.

Inflammatory phenotyping

MABVIEWER delivers a step change in inflammatory phenotyping for novel target identification and validation.

A molecular imaging approach to precision medicine

MABVIEWER leverages existing molecular imaging technology, combined with our AI-enhanced algorithms to deliver a revolutionary approach to precision medicine.

The MABVIEWER platform

Bringing molecular imaging to the clinic

MABVIEWER overcomes the complexity usually associated with molecular imaging, allowing the full potential of this technique to be realised, delivering real value to physicians and patients.

CloudComputing_EditedNoBackground_growtika-wlQUkvDhvQw-unsplash.png

Cloud-based architecture

MABVIEWER will utilise a fully cloud-based architecture, enabling us to deliver value to physicians and patients on a global scale.

The Team

Mark Timbrell

Mark Timbrell leads commercialisation and investor relations. His CV includes founding a marketing services group serving blue chip brands through 48 offices worldwide with billings of $700 million. After a successful exit he has also founded businesses focussed on social impact; Go Henry and Sort Your Future.

Tom Wilkinson

Tom is a co-inventor of the MABVIEWER platform and a co-founder of Precision Clinical Intelligence Ltd. He leads clinical innovation. He is a Professor of Respiratory Medicine and Honorary Consultant in Respiratory and General Medicine, University of Southampton.

Michael Bennett

Michael is a co-inventor of the MABVIEWER platform technology and a co-founder of Precision Clinical Intelligence Ltd. He leads on AI, data science and platform development. He has worked in the area of medical image analysis for the last 20 years, including 15 years working within the NHS.

Helen Davies

Helen has a 35 year experience in global pharmaceutical development from within major pharma and services company. She is accountable for the strategic development and achievement of progress with MABVIEWER.

Camille King

Camille King provides support to investor relations and commercialisation, technology strategy and operations, and business analysis. She previously worked at Accenture and Barclays, where she developed expertise implementing trading systems and financial modelling platforms in Europe, North America and Asia. She obtained a Master's degree in Management at the University of Lyon and an MBA at the University of South Florida, and is fluent in French.

Dan Allen

Dan Allen is an ex-PWC and Bertelsmann Group Chartered Accountant with a broad mix of international corporate and startup experience over a 35 year career. At PCI he will manage all aspects of finance and corporate admin including bookkeeping, payroll, budgeting, financial modelling, corporate reporting, cost control and company secretarial.

A short video introduction to MABVIEWER from Professor Tom Wilkinson, co-founder of Precision Clinical Intelligence Ltd.

An introduction to the MABVIEWER technology from Dr Michael Bennett,
co-founder of Precision Clinical Intelligence Ltd.

Contact Us

If you would like to know more about MABVIEWER, then please get in touch using the form below.

from Precision Clinical Intelligence Ltd